NovoCure Q3 Revenue Rises 16% to $193.4M, Raises 2026 Guidance
NovoCure reported Q3 2026 revenue of $193.4M, up 16% YoY, and a net loss of $10.4M. Adjusted EBITDA was $15.7M. The company raised its 2026 revenue and EBITDA guidance. Active patients for its therapies increased, with Optune Gio up 11% and Optune Lua up 83% YoY. Japan approved Optune Pax for pancreatic cancer. NovoCure also announced a clinical trial collaboration with Verastem Oncology.
How this was made

The 30-second read
Why it matters
The earnings beat and guidance raise provide fresh material that can trigger short‑term price moves and influence analyst outlooks.
Market read
Guidance lift is the primary catalyst for potential upside in NVCR, with broader relevance to the oncology device sector.
What to watch
Cash runway of $463.5M reduces near‑term financing risk, but competitive landscape in TTFields could pressure future growth.
Background
NovoCure is a biotech firm commercializing Tumor Treating Fields therapy for solid tumors, with recent regulatory approvals in Japan and ongoing FDA reviews.
Ticker impact
NovoCure reported Q3 2026 revenue up 16% YoY to $193.4M and raised full-year revenue guidance to $736M‑$743M.
likely upward pressure as investors price in higher revenue outlook
Revenue beat and guidance lift are fresh primary disclosures that can move the stock immediately.
Market effects
Positive signal for oncology/medical‑device sector as TTFields therapy gains traction.
U.S. biotech market may see modest uplift from NovoCure's guidance raise.
Limited to investors focused on cancer‑treatment technologies.
Counterpoint
If the FDA decision on brain metastases is delayed, the guidance may be overly optimistic.
Key entities
- companyNovoCure Ltd
Developer of TTFields therapy, listed on NYSE as NVCR.
- companyVerastem Oncology
Partner in clinical trial collaboration with NovoCure.

